42 completed, 30 terminated, 6 withdrawn, 2 unknown. 42 Phase 2, 26 Phase 1, 19 Phase 3.
Follow Spectrum Pharmaceuticals, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations Poziotinib, Docetaxel - NSCLC | Phase 3 | Suspended | Spectrum Pharmaceuticals, Inc | 268 | 2022-05-12 | 2026-09-30 |
| A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy Eflapegrastim, Chemotherapy - Solid Tumors, Lymphoma | Phase 2 | Recruiting | Spectrum Pharmaceuticals, Inc | 40 | 2021-05-20 | 2026-09-30 |
| A Study to Evaluate the Effect of Multiple Doses of Itraconazole, Phenytoin, and Paroxetine on the Single-Dose Pharmacokinetics of Poziotinib in Healthy Adult Participants Poziotinib, Itraconazole, Phenytoin - Healthy | Phase 1 | Completed | Spectrum Pharmaceuticals, Inc | 74 | 2021-04-08 | 2021-09-05 |
| A Study of IGN002 for Refractory NHL IGN002 - NHL | Phase 1 | Withdrawn | Spectrum Pharmaceuticals, Inc | 2021-01-01 | 2022-03-11 | |
| Study of Poziotinib in Japanese Patients With NSCLC Poziotinib Once Daily Dosing, Poziotinib Twice Daily Dosing, Poziotinib Once Daily Dosing or Twice Daily Dosing as determined in Phase 1 - NSCLC | Phase 1 / Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 42 | 2020-06-23 | 2024-06-25 |
| Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects [14C]-Poziotinib - Healthy | Phase 1 | Completed | Spectrum Pharmaceuticals, Inc | 8 | 2020-05-29 | 2021-01-15 |
| Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer Eflapegrastim, Docetaxel, Cyclophosphamide - Neutropenia, Breast Cancer | Phase 1 | Completed | Spectrum Pharmaceuticals, Inc | 59 | 2020-03-11 | 2024-09-19 |
| A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies Poziotinib Hydrochloride, Loperamide - Breast Cancer, Colorectal Cancer | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 1 | 2019-12-23 | 2024-03-13 |
| A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib 14C-labeled poziotinib - Solid Tumor | Phase 1 | Terminated | Spectrum Pharmaceuticals, Inc | 2 | 2019-06-25 | 2021-06-15 |
| A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib Poziotinib - NSCLC, Breast Cancer | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 7 | 2018-10-11 | 2026-07-28 |
| A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast Cancer Poziotinib, T-DM1 - Breast Cancer | Phase 1 | Terminated | Spectrum Pharmaceuticals, Inc | 6 | 2018-07-13 | 2021-01-15 |
| Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Propylene Glycol-Free Melphalan Hydrochloride - Amyloidosis; Systemic | Phase 2 | Terminated | Boston Medical Center | 27 | 2018-01-08 | 2023-05-24 |
| Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation Poziotinib - NSCLC | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 648 | 2017-10-11 | 2026-06-12 |
| A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT) Qapzola, Placebo - Bladder Cancer | Phase 3 | Terminated | Spectrum Pharmaceuticals, Inc | 118 | 2017-08-04 | 2021-09-28 |
| Pharmacokinetics of SPI-2012 (Eflapegrastim) in Breast Cancer Patients Receiving Docetaxel and Cyclophosphamide (TC) Chemotherapy SPI-2012 - Breast Cancer, Pharmacokinetics | Phase 1 | Completed | Spectrum Pharmaceuticals, Inc | 26 | 2017-05-11 | 2020-11-13 |
| SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide SPI-2012, Pegfilgrastim, Docetaxel - Neutropenia, Breast Cancer | Phase 3 | Completed | Spectrum Pharmaceuticals, Inc | 237 | 2017-05-10 | 2022-03-02 |
| Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma Rituximab, Bendamustine, Vincristine sulfate liposome injection - Lymphoma, Non-Hodgkin, Lymphoma, Follicular | Phase 1 | Completed | Brown University | 11 | 2017-05-10 | 2023-02-09 |
| Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC Poziotinib - EGFR Exon 20 Mutation, ERBB2 Gene Mutation | Phase 2 | Terminated | M.D. Anderson Cancer Center | 93 | 2017-03-17 | 2026-02-20 |
| Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy Marqibo - ALL, Childhood, Lymphoblastic Leukemia, Acute, Childhood | Phase 1 | Completed | Therapeutic Advances in Childhood Leukemia Consortium | 29 | 2017-01-31 | 2025-10-22 |
| Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma Dexamethasone, Panobinostat, Liposomal vincristine - Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's | Phase 2 | Terminated | St. Jude Children's Research Hospital | 3 | 2016-11-23 | 2019-04-03 |
Showing 20 of 83. Sign in to see all of them.
Lymphoma, Non-Hodgkin (11) · Breast Neoplasms (10) · Carcinoma, Non-Small-Cell Lung (8) · Urinary Bladder Neoplasms (8) · Lymphoma (7) · Lymphoma, Follicular (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Leukemia (5) · Lymphoma, Large B-Cell, Diffuse (5) · Lymphoma, Mantle-Cell (5) · Lung Neoplasms (4) · Neoplasms (4) · Neutropenia (4) · Brain Neoplasms (3) · Hodgkin Disease (3)
Rituximab (10) · Vincristine (10) · ibritumomab tiuxetan (9) · Docetaxel (8) · Cyclophosphamide (7) · HM781-36B (7) · apaziquone (7) · belinostat (7) · 10-propargyl-10-deazaaminopterin (6) · eflapegrastim (6) · pegfilgrastim (5) · efaproxiral (4) · Bendamustine Hydrochloride (3) · Calcium Dobesilate (3) · Carboplatin (3)
United States (77) · Canada (17) · United Kingdom (9) · France (8) · Belgium (7) · Hungary (7) · Israel (7) · Italy (7) · Poland (7) · Germany (6) · Spain (6) · Australia (5) · Denmark (4) · Netherlands (4) · Austria (3)
Shanta Chawla, MD (7) · Hak Choy, MD (2) · Show-Li Sun, MD (2) · Adam J Olszewski, MD (1) · Adam Lerner, MD (1) · Alfred Witjes, MD, Prof. (1) · Amanda Cashen, MD (1) · Andreas K Klein, MD (1) · Andreas Neubauer, MD (1) · Andreas Viardot, MD (1) · Andrei Shustov, MD (1) · Andrew M Evens, DO, MSc (1) · Ann Mohrbacher, MD (1)
PMID 16135463, PMID 16314619, PMID 19652067, PMID 20978276, PMID 23169518, PMID 23907766, PMID 26921086, PMID 29573207, PMID 30239252, PMID 33928400, PMID 34550757, PMID 34843401, PMID 35641232, PMID 35820397, PMID 37607644, PMID 39727283, PMID 39937083, PMID 40782807
2008 (1), 2016 (1), F30CA206291 (1), P30CA012197 (1), P30CA036727 (1), P30CA138292 (1), R21NS100244 (1), U01CA172027 (1)